Quigley Corp. officially appoints interim CEO Karkus to post
DOYLESTOWN, Pa. Quigley Corp. on Friday named Ted Karkus, chairman, the company’s CEO.
Robert Cuddihy has been appointed COO.
Karkus recently conducted a successful proxy contest which resulted in his slate of directors being elected to the board last month. He had been serving as interim CEO since June 12.
Karkus has 25 years of Wall Street experience and since 1996 has been providing management consulting services to emerging-growth companies. Karkus assisted the turnaround of ID Biomedical, an influenza vaccine manufacturer, which in 2005 was sold to GlaxoSmithKline for more than $1.4 billion.
Cuddihy has more than 20 years of experience as the COO and/or CFO of two public companies — HMG Worldwide Corporation, which focused on retail, planning and merchandising; and iDNA Inc., which focused on corporate communications. Most recently, Cuddihy served as the president of Shannon Hill Associates.
Former chairman, president and CEO Guy Quigley announced his resignation last month, following a contentious proxy contest which culminated on May 20 at the company’s annual meeting and favored shareholder Karkus and his proposed slate of directors.
Quigley Co. also accepted the resignation of Charles Phillips, COO, and Wendy Quigley, accounting operations manager, last month.
CDC: School children may need four immunizations this fall
NEW YORK School children may need as many as four immunizations against both seasonal flu and the novel H1N1 virus this year, Centers for Disease Control and Prevention officials told clinicians Wednesday, according to published reports.
That regimen includes an initial shot and booster of both vaccines for children. Most everyone else will only need to get their regular seasonal shot and two shots for the novel H1N1 vaccine, when one is available.
Five manufacturers are currently producing vaccines against the pandemic H1N1 swine flu virus — CSL Biotherapies, GlaxoSmithKline, Medimmune, Novartis and Sanofi Pasteur.
The five manufacturers are expected to deliver between 40 million and 160 million doses of vaccine by October. The regular seasonal flu vaccine supply will be ready much earlier than usual, possibly as soon as late August.
According to CDC officials, pandemic flu shots will be allocated among states based on their population.
Nature & Health announces voluntary, nationwide recall of five supplement products
BREA, Calif. Nature & Health on Wednesday conducted a voluntary nationwide recall of the company’s five supplement products sold under the following names — LibieXtreme, Y-4ever, Libimax X Liquid, Powermania Liquid and Capsule and Herbal Disiac — after being informed by the Food and Drug Administration that lab analyses of these five products found they contained either tadalafil, an active ingredient of an FDA-approved drug for erectile dysfunction; its analog aminotadalafil; or the analog of sidenafil, another active ingredient of an FDA-approved ED drug.
None of the active drug ingredients are listed on the product labels.
The undeclared ingredients may interact with nitrates found in such prescription drugs as nitroglycerin and may lower blood pressure to dangerous levels. Consumers with diabetes, high blood pressure, high cholesterol or heart disease often take nitrates.
Additionally, the product may cause such side effects as headaches and flushing.
The recalled products were distributed in retail stores in California, Georgia, Illinois, Texas and Ohio.